Literature DB >> 22394547

Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.

M Decressac1, B Mattsson, A Björklund.   

Abstract

Development of relevant models of Parkinson's disease (PD) is essential for a better understanding of the pathological processes underlying the human disease and for the evaluation of promising targets for therapeutic intervention. To date, most pre-clinical studies have been performed in the well-established rodent and non-human primate models using injection of 6-hydroxydopamine (6-OHDA) or 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine (MPTP). Overexpression of the disease-causing protein α-synuclein (α-syn), using adeno-associated viral (AAV) vectors, has provided a novel model that recapitulates many features of the human disease. In the present study we compared the AAV-α-syn rat model with models where the nigro-striatal pathway is lesioned by injection of 6-OHDA in the striatum (partial lesion) or the medial forebrain bundle (full lesion). Examination of the behavioural changes over time revealed a different progression and magnitude of the motor impairment. Interestingly, dopamine (DA) neuron loss is prominent in both the toxin and the AAV-α-syn models. However, α-syn overexpressing animals were seen to exhibit less cell and terminal loss for an equivalent level of motor abnormalities. Prominent and persistent axonal pathology is only observed in the α-syn rat model. We suggest that, while neuronal and terminal loss mainly accounts for the behavioural impairment in the toxin-based model, similar motor deficits result from the combination of cell death and dysfunction of the remaining nigro-striatal neurons in the AAV-α-syn model. While the two models have been developed to mimic DA neuron deficiency, they differ in their temporal and neuropathological characteristics, and replicate different aspects of the pathophysiology of the human disease. This study suggests that the AAV-α-syn model replicates the human pathology more closely than either of the other two 6-OHDA lesion models.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22394547     DOI: 10.1016/j.expneurol.2012.02.012

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  43 in total

1.  Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice.

Authors:  A M Willard; R S Bouchard; A H Gittis
Journal:  Neuroscience       Date:  2015-06-09       Impact factor: 3.590

2.  RING finger protein 11 (RNF11) modulates susceptibility to 6-OHDA-induced nigral degeneration and behavioral deficits through NF-κB signaling in dopaminergic cells.

Authors:  Elaine L Pranski; Nirjari V Dalal; Carson Van Sanford; Jeremy H Herskowitz; Marla Gearing; Carlos Lazo; Gary W Miller; James J Lah; Allan I Levey; Ranjita S Betarbet
Journal:  Neurobiol Dis       Date:  2013-01-11       Impact factor: 5.996

Review 3.  How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?

Authors:  Laura A Volpicelli-Daley; Deniz Kirik; Lindsay E Stoyka; David G Standaert; Ashley S Harms
Journal:  J Neurochem       Date:  2016-05-04       Impact factor: 5.372

Review 4.  Impulse control disorders in Parkinson's disease.

Authors:  Ana Marques; Franck Durif; Pierre-Olivier Fernagut
Journal:  J Neural Transm (Vienna)       Date:  2018-03-07       Impact factor: 3.575

5.  Loss of MicroRNA-7 Regulation Leads to α-Synuclein Accumulation and Dopaminergic Neuronal Loss In Vivo.

Authors:  Kirsty J McMillan; Tracey K Murray; Nora Bengoa-Vergniory; Oscar Cordero-Llana; Jane Cooper; Amy Buckley; Richard Wade-Martins; James B Uney; Michael J O'Neill; Liang F Wong; Maeve A Caldwell
Journal:  Mol Ther       Date:  2017-08-31       Impact factor: 11.454

6.  KM-34, a Novel Antioxidant Compound, Protects against 6-Hydroxydopamine-Induced Mitochondrial Damage and Neurotoxicity.

Authors:  Luis Arturo Fonseca-Fonseca; Yanier Nuñez-Figueredo; Jeney Ramírez Sánchez; Maylin Wong Guerra; Estael Ochoa-Rodríguez; Yamila Verdecia-Reyes; René Delgado Hernádez; Noelio J Menezes-Filho; Teresa Cristina Silva Costa; Wagno Alcântara de Santana; Joana L Oliveira; Juan Segura-Aguilar; Victor Diogenes Amaral da Silva; Silva Lima Costa
Journal:  Neurotox Res       Date:  2018-01-02       Impact factor: 3.911

7.  Downregulation of lncRNA BACE1-AS improves dopamine-dependent oxidative stress in rats with Parkinson's disease by upregulating microRNA-34b-5p and downregulating BACE1.

Authors:  Yanhong Li; Jian Fang; Zhanye Zhou; Qiyu Zhou; Shibin Sun; Zhikai Jin; Ziming Xi; Jianshe Wei
Journal:  Cell Cycle       Date:  2020-04-19       Impact factor: 4.534

8.  Triptolide Promotes the Clearance of α-Synuclein by Enhancing Autophagy in Neuronal Cells.

Authors:  Guanzheng Hu; Xiaoli Gong; Le Wang; Mengru Liu; Yang Liu; Xia Fu; Wei Wang; Ting Zhang; Xiaomin Wang
Journal:  Mol Neurobiol       Date:  2016-03-09       Impact factor: 5.590

9.  TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity.

Authors:  Mickael Decressac; Bengt Mattsson; Pia Weikop; Martin Lundblad; Johan Jakobsson; Anders Björklund
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-22       Impact factor: 11.205

10.  Pramipexole induced place preference after L-dopa therapy and nigral dopaminergic loss: linking behavior to transcriptional modifications.

Authors:  Simon Loiodice; Poppy Winlow; Sarah Dremier; Etienne Hanon; David Dardou; Omar Ouachikh; Aziz Hafidi; Andre Nogueira da Costa; Franck Durif
Journal:  Psychopharmacology (Berl)       Date:  2016-09-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.